CGTLive®’s Weekly Rewind – March 22, 2024

News
Article

Review top news and interview highlights from the week ending March 22, 2024.

CGTLive®’s Weekly Rewind – March 22, 2024

CGTLive®’s Weekly Rewind – March 22, 2024


Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FDA Approves Orchard Therapeutics’ Gene-Edited Cell Therapy Arsa-Cel for Metachromatic Leukodystrophy

Arsa-cel, approved under the name Lenmeldy, is set to be priced at $4.25 million.

2. Robert J. Hopkin, MD, on Safely Delivering Gene Therapy for Fabry Disease

The associate professor of clinical pediatrics at Cincinnati Children's discussed the latest data from the phase 1/2 STAAR study of isaralgagene civaparvovec.

3. Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD

The gene-edited cell therapy has been approved as Lenmeldy by the FDA.

4. Atul Malhotra, MD, PhD, on the Importance of Preclinical Work for Bringing Cell Therapies to Clinic

The head of the early neurodevelopment clinic at Monash Children's Hospital discussed preclinical work in the context of neonatal cell therapy research.

5. Patients With Hemophilia Biding Their Time for Gene Therapy

Many surveyed participants were content with current treatments or wary of gene therapy’s adverse events and durability.

Recent Videos
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Chun-Yu Chen, PhD, a research scientist at Seattle Children’s Research Institute
William Chou, MD, on Targeting Progranulin With Gene Therapy for Frontotemporal Dementia
Alexandra Collin de l’Hortet, PhD, the head of therapeutics at Epic Bio
David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI David Dimmock, MBBS, on Accelerating Therapy Discovery and Approval With AI
Joshua M. Hare, MD, on Working to Address Unmet Needs in Alzheimer Disease With Lomecel-B Cell Therapy
Related Content
© 2024 MJH Life Sciences

All rights reserved.